University of Occupational and Environmental Health Japan

www.uoeh-u.ac.jp
Fukuoka, Japan

University of Occupational and Environmental Health Japan is a private university in Kitakyushu City, Fukuoka Prefecture, Japan, established in 1978. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
University of Occupational, Environmental Health Japan and Sbi Pharmaceuticals Co. | Date: 2015-02-19

[Problem to be Solved] It is an object of the present invention to provide a composition, which induces immunity to tumor cells and is also able to induce inhibition of tumor growth. [Solution] Provided is a composition for inducing tumor immunity, comprising ALAs.


Patent
Kumamoto University, University of Occupational, Environmental Health Japan and SBI Pharmaceuticals Co. | Date: 2013-12-09

[Problem] To provide a nuclear magnetic resonance diagnostic agent that has a lower toxicity to organisms and reduced side effects and yet has a site specificity toward a specific cell, tissue, organ, etc. [Solution] When ALA or an ALA derivative is administered in vivo, a metabolite thereof is accumulated in a specific cell, tissue, organ, etc. Focusing on this phenomenon, a nuclear magnetic resonance analysis was performed on a site wherein the metabolite of ALA that had been administered in vivo would be possibly accumulated. As a result, it was surprisingly found that ALA and an ALA derivative are useful as a diagnostic agent whereby the aforesaid problem can be solved.


Patent
Kumamoto University, University of Occupational, Environmental Health Japan and SBI Pharmaceuticals Co. | Date: 2015-10-21

[Problem] To provide a nuclear magnetic resonance diagnostic agent that has a lower toxicity to organisms and reduced side effects and yet has a site specificity toward a specific cell, tissue, organ, etc. [Solution] When ALA or an ALA derivative is administered in vivo, a metabolite thereof is accumulated in a specific cell, tissue, organ, etc. Focusing on this phenomenon, a nuclear magnetic resonance analysis was performed on a site wherein the metabolite of ALA that had been administered in vivo would be possibly accumulated. As a result, it was surprisingly found that ALA and an ALA derivative are useful as a diagnostic agent whereby the aforesaid problem can be solved.


Tokura Y.,University of Occupational and Environmental Health Japan
Journal of Dermatological Science | Year: 2010

Atopic dermatitis (AD) can be categorized into the extrinsic and intrinsic types. Extrinsic or allergic AD shows high total serum IgE levels and the presence of specific IgE for environmental and food allergens, whereas intrinsic or non-allergic AD exhibits normal total IgE values and the absence of specific IgE. While extrinsic AD is the classical type with high prevalence, the incidence of intrinsic AD is approximately 20% with female predominance. The clinical features of intrinsic AD include relative late onset, milder severity, and Dennie-Morgan folds, but no ichthyosis vulgris or palmar hyperlinearity. The skin barrier is perturbed in the extrinsic, but not intrinsic type. Filaggrin gene mutations are not a feature of intrinsic AD. The intrinsic type is immunologically characterized by the lower expression of interleukin (IL) -4, IL-5, and IL-13, and the higher expression of interferon-γ. It is suggested that intrinsic AD patients are not sensitized with protein allergens, which induce Th2 responses, but with other antigens, and metals might be one of the candidates of such antigens. © 2010 Japanese Society for Investigative Dermatology.


Tanaka Y.,University of Occupational and Environmental Health Japan
Annals of the Rheumatic Diseases | Year: 2013

Biological agents targeting tumour necrosis factor (TNF) have revolutionised the treatment of rheumatoid arthritis (RA) and clinical remission has become a realistic treatment goal. Discontinuing anti-TNF therapy after sustained remission has emerged as an important area of investigation in rheumatology from the risk-benefit point of view, including health economic considerations. However, there is little information as to whether 'biologic-free remission' is possible after sustained remission following intensive treatment with TNF inhibitors in RA. European studies such as BeSt and OPTIMA in patients with early RA and Japanese studies such as remission induction by remicade in patients with RA and HONOR in patients with long-standing RA encountered during routine clinical practice have shown that, after a reduction in disease activity to clinical remission or low disease activity by infliximab or adalimumab in combination with methotrexate, patients can successfully remain in clinical remission without TNF inhibitors with no radiological and functional damage progression of articular destruction. Experimental findings in TNF-deficient mouse models suggest that TNF inhibitors may change the disease process of RA and bring about the potential of immunological remission, raising the possibility of a 'treatment holiday' of TNF inhibitors after intensive treatment.


Tanaka Y.,University of Occupational and Environmental Health Japan
Current Opinion in Rheumatology | Year: 2012

Purpose of Review: Biologics targeting tumor necrosis factor (TNF) has revolutionized the treatment of rheumatoid arthritis (RA) and clinical remission becomes a realistic treatment goal. After achieving remission, discontinuation of TNF inhibitors may become an important issue from viewing points of safety and economy. However, there is not well established firm evidence regarding biologic-free remission. We here document whether 'treatment holiday' of TNF inhibitors is possible in RA patients, after maintaining low disease activity by intensive treatment with TNF inhibitors. Recent Finding: From European studies such as BeSt and OPTIMA in patients with early RA and Japanese studies such as RRR and HONOR in patients with established RA, after reduction of disease activity to clinical remission or low disease activity in patients with RA by infliximab or adalimumab in combination with methotrexate, some patients could successfully remain in clinical remission without TNF inhibitors for 6 months or 1 year and without radiologic and functional progression of articular destruction. Summary: After maintaining low disease activity by intensive treatment with TNF inhibitors, discontinuation of TNF inhibitors without disease flare, joint damage progression and functional impairment, treatment holiday, is possible in some RA patients. © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.


There is currently little information on the medical economic outcomes of endoscopic submucosal dissection (ESD) for gastric cancer (GC) in elderly patients. This study therefore aimed to investigate the medical economic outcomes of ESD in elderly patients with GC using a national administrative database. A total of 27 385 patients treated with ESD for GC were referred to 867 hospitals in Japan from 2009 to 2011. We collected data from the national administrative database and divided them into two groups according to age: elderly patients (≥80 years; n = 5525) and non-elderly patients (<80 years; n = 21 860). We compared ESD-related complications, risk-adjusted length of stay (LOS) and medical costs during hospitalization between elderly and non-elderly patients. There was no significant difference in ESD-related complications between elderly and non-elderly patients (4.3% vs 3.9%, P = 0.152). However, significant differences were observed in mean LOS and medical costs during hospitalization between the two groups (P < 0.001). Multiple linear regression analysis showed that elderly patients experienced a significantly longer LOS and higher medical costs. The unstandardized coefficient for LOS in elderly patients was 2.71 days (95% confidence interval [CI] 2.59-2.84, P < 0.001), while that for medical costs during hospitalization was USD952.1 (95% CI 847.7-1056.5, P < 0.001). LOS and medical costs during hospitalization were significantly higher in elderly patients undergoing ESD for GC than in non-elderly patients, although there was no difference in the incidence of ESD-related complications. © 2013 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.


Koga Y.,University of Occupational and Environmental Health Japan
Archaea | Year: 2012

The physiological characteristics that distinguish archaeal and bacterial lipids, as well as those that define thermophilic lipids, are discussed from three points of view that (1) the role of the chemical stability of lipids in the heat tolerance of thermophilic organisms: (2) the relevance of the increase in the proportion of certain lipids as the growth temperature increases: (3) the lipid bilayer membrane properties that enable membranes to function at high temperatures. It is concluded that no single, chemically stable lipid by itself was responsible for the adaptation of surviving at high temperatures. Lipid membranes that function effectively require the two properties of a high permeability barrier and a liquid crystalline state. Archaeal membranes realize these two properties throughout the whole biological temperature range by means of their isoprenoid chains. Bacterial membranes meet these requirements only at or just above the phase-transition temperature, and therefore their fatty acid composition must be elaborately regulated. A recent hypothesis sketched a scenario of the evolution of lipids in which the lipid divide emerged concomitantly with the differentiation of archaea and bacteria. The two modes of thermal adaptation were established concurrently with the lipid divide. © 2012 Yosuke Koga.


Abe H.,University of Occupational and Environmental Health Japan
Journal of Arrhythmia | Year: 2012

State-of-the-art, implantable, dual-chamber cardiac devices provide useful diagnostic information, including the number and duration of automatic-mode switch episodes in cases of atrial tachycardia and atrial fibrillation encountered in clinical practice. However, to acquire accurate diagnostic information, special attention must be paid to the device settings; to the presence or absence of ventriculoatrial conduction, which, when present, often represents repetitive non-reentrant synchrony (RNRVAS) or pacemaker-mediated tachycardia; to the post-ventricular atrial-blanking period and atrial sensitivity; and to the sensing of far-field R waves (FFRW) in the atrial channel. Physicians should be careful about the information gathered during the monitoring of patients with implantable devices. © 2012 Japanese Heart Rhythm Society.


Patent
University of Occupational and Environmental Health Japan | Date: 2013-05-08

An exercise training apparatus 10 attached to a trainee who performs a body exercise training, includes movable bodies 11, 12, actuators 13, 14, change detecting means 15, 16 and a controlling means 25, the movable bodies 11, 12 having fixed members 11a, 12a which a part of a trainees body is fixed to and exercising a trainees extremities by rotating around shafts 19, 22, respectively, the change detecting means 15, 16 each detecting a physical quantity that changes depending on force applied to the fixed members 11a, 12a by a trainee, the controlling means 25, in response to a detection of a predetermined change in a physical quantity by the change detecting means 15, 16, driving the actuators 13, 14, rotating the movable bodies 11, 12 in a first direction and successively rotating the movable bodies 11, 12 in a second direction opposite to the first direction.

Loading University of Occupational and Environmental Health Japan collaborators
Loading University of Occupational and Environmental Health Japan collaborators